Apnimed Inc. (APMD)
NASDAQ: APMDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
APMD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $669.84M
- P/E (TTM)
- 1.21
- EPS (TTM)
- $13.34
- Dividend yield
- None
- 52-week range
- 13.88 – 35.29
- Day range
- 15.95 – 17.73
- Volume / Avg
- 248.59K / 458.58K
- Beta
- —
- Shares outstanding
- 41.63M
- Next earnings
- Dec 8, 2026
52-week range
APMD stock today
Apnimed (APMD) closed at $16.09 on Nov 20, down 6.70% (-$1.16), versus the S&P 500's 3.70% decline. At this level, APMD sits near the bottom of its 52-week range of $13.88 to $35.29: 54.4% below the high, set on Aug 18, 2026 and 15.9% above the low. Apnimed trades at 1.2x its trailing twelve-month earnings per share of $13.34.
The company is scheduled to report Sep/2026 results on Dec 8.
Summary generated from market data by MetaCap's automated system. Methodology
About Apnimed
Company profileApnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Kevin Robert Lind
- Headquarters
- Cambridge, MA
- Employees
- 112
- IPO year
- 2026
- Website
- apnimed.com
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$50.00+210.75%
- Strong buy 0
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Dec 8, 2026
- Last reported (Sep/2026)
- Dec 8, 2026
- EPS actual vs est.
- $-1.05 vs —
APMD news
All APMD newsApnimed peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NVCTNuvectis Pharma Inc. | 19.39 | -2.27% | $666.80M | vs APMD |
| LXRXLexicon Pharmaceuticals Inc. | 1.53 | -8.38% | $681.21M | vs APMD |
| SGMTSagimet Biosciences Inc. Series A | 9.08 | -5.61% | $648.02M | vs APMD |
| KURAKura Oncology Inc. | 6.91 | -5.99% | $634.88M | vs APMD |
| JANXJanux Therapeutics Inc. | 10.08 | -2.04% | $616.73M | vs APMD |
| ABUSArbutus Biopharma Corporation | 4.02 | -1.23% | $616.24M | vs APMD |
| OLMAOlema Oncology Inc. | 7.02 | -1.82% | $615.00M | vs APMD |
| OBXObsidian Therapeutics Inc. | 12.00 | -1.23% | $741.29M | vs APMD |
Indexes, lists and sector
Apnimed stock FAQ
What is Apnimed's stock price today?
APMD last traded at $16.09 as of Nov 20, 4:00 PM EST, down 6.70% on the day. Prices are delayed at least 15 minutes.
When is Apnimed's next earnings date?
Apnimed is expected to report earnings on Tuesday, December 8, 2026.
What is APMD's P/E ratio?
APMD trades at a trailing P/E ratio of 1.21.
Who is Apnimed's CEO?
Mr. Kevin Robert Lind is the chief executive officer of Apnimed Inc., which has about 112 employees.
What is the APMD 52-week high?
The 52-week high for APMD is $35.29 and the 52-week low is $13.88. The stock is currently 54.4% below its high.